World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
24759
World Ranking
11462
National Ranking
5874

Rajyalakshmi Luthra publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Rajyalakshmi Luthra sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 440 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Rajyalakshmi Luthra D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Rajyalakshmi Luthra sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Rajyalakshmi Luthra is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on cancer-related studies.

The main subfields of study for their work include Cancer Research, Hematology, Oncology, Molecular Biology, and Pathology and Forensic Medicine. Their research topics cover a diverse range of cancer-specific areas such as Cancer Genomics and Diagnostics, Acute Myeloid Leukemia Research, Lung Cancer Treatments and Mutations, Genetic Factors in Colorectal Cancer, RNA Modifications and Cancer, and Lymphoma Diagnosis and Treatment, as well as Cancer Immunotherapy and Biomarkers.

They have published extensively, with frequent articles appearing in several key academic journals. The most common venues for their publications are:

  • Cancer Genetics
  • Journal of Clinical Oncology
  • Blood
  • Cancer Cytopathology
  • Cancers

Rajyalakshmi Luthra frequently collaborates with a number of coauthors, including:

  • Keyur P. Patel
  • L. Jeffrey Medeiros
  • Rashmi Kanagal-Shamanna
  • Dzifa Y. Duose
  • Mark J. Routbort

Recent publications by Rajyalakshmi Luthra include the following:

  • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity (2022, Cancer Cell)
  • High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance (2022, Leukemia)
  • Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia (2020, Blood Advances)
  • Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers (2020, Cancer Cytopathology)
  • Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial (2024, Clinical Cancer Research)

Best Publications

  • Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Apostolia M. Tsimberidou;Nancy G. Iskander;David S. Hong;Jennifer J. Wheler

  • PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

    Filip Janku;Jennifer J. Wheler;Shannon N. Westin;Stacy L. Moulder

  • Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

    Alfonso Quintás-Cardama;Hagop Kantarjian;Taghi Manshouri;Rajyalakshmi Luthra

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression

    Z. Chen;Yu-Hong Li;H. Zhang;Peng Huang

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.

    Karen H. Lu;John O. Schorge;Kerry J. Rodabaugh;Molly S. Daniels

  • Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes

    Rajesh R. Singh;Keyur P. Patel;Mark J. Routbort;Neelima G. Reddy

  • Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

    Jorge Cortes;Moshe Talpaz;Susan O'Brien;Dan Jones

  • Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma.

    Russell R. Broaddus M.D.;Henry T. Lynch;Lee-may Chen;Molly S. Daniels

  • Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: An uncontrolled trial

    Gideon Steinbach;Richard Ford;Gary Glober;Dory Sample

  • MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers

    Rajyalakshmi Luthra;Rajesh R Singh;M. G. Luthra;Y. X. Li

  • PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

    Filip Janku;Jennifer J. Wheler;Aung Naing;Gerald S. Falchook

  • Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes

    Jonathan M Loree;Allan Al Pereira;Michael Lam;Alexandra N Willauer

  • Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

    Filip Janku;David S. Hong;Siqing Fu;Sarina A. Piha-Paul

  • Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab

    Yasmin Abaza;Hagop M. Kantarjian;Guillermo Garcia-Manero;Elihu Estey

  • Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α

    Hagop M. Kantarjian;Jorge E. Cortes;Susan O'Brien;Rajyalakshmi Luthra

  • Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

    Farhad Ravandi;Jeffrey L. Jorgensen;Deborah A. Thomas;Susan O'Brien

  • PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

    Filip Janku;J. Jack Lee;Apostolia M. Tsimberidou;David S. Hong

  • Effects of Cyclin D1 Polymorphism on Age of Onset of Hereditary Nonpolyposis Colorectal Cancer

    Shouming Kong;Christopher I. Amos;Rajyalakshmi Luthra;Patrick M. Lynch

Frequent Co-Authors

L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Russell Broaddus
Russell Broaddus University of North Carolina at Chapel Hill
Susan O'Brien
Susan O'Brien University of California, Irvine
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but exploring alternative paths, a variety of online health degrees can open rewarding careers. Many students are now considering flexible programs that fit different interests and schedules — from direct patient care to behind-the-scenes roles in healthcare.

For those drawn to pharmacy, pharmacy school online accredited programs offer a path to highly respected roles with competitive salaries. If your strengths include technology and organization, a health information technology online degree can lead to essential positions involving medical records and data management.

Entry into the field is also possible via administrative roles. Wondering how much does it cost to become a medical coder? Online programs make it affordable and accessible to enter this in-demand specialty. For those seeking advanced clinical careers, there are now numerous online nurse practitioner programs to help registered nurses reach the next level in practice and patient care.

Best Scientists Citing Rajyalakshmi Luthra

Trending Scientists

Recently Published Articles